TY - JOUR
T1 - Intraventricular immunovirotherapy; a translational step forward
AU - Bernstock, Joshua D.
AU - Blitz, Sarah
AU - Kang, Kyung Don
AU - Friedman, Gregory K.
N1 - Publisher Copyright:
© 2023 Bernstock et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023
Y1 - 2023
N2 - Oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease. A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207.
AB - Oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease. A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207.
KW - G207
KW - herpes simplex virus (HSV)
KW - intraventricular therapy
KW - leptomeningeal disease
KW - oncolytic virotherapy
UR - http://www.scopus.com/inward/record.url?scp=85173805884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173805884&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.28343
DO - 10.18632/oncotarget.28343
M3 - Article
C2 - 36634220
AN - SCOPUS:85173805884
SN - 1949-2553
VL - 14
SP - 40
EP - 43
JO - Oncotarget
JF - Oncotarget
ER -